STOCK TITAN

Bausch + Lomb Corp - BLCO STOCK NEWS

Welcome to our dedicated news page for Bausch + Lomb (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bausch + Lomb's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bausch + Lomb's position in the market.

Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) announced the appointment of Karen L. Ling to its Board of Directors, with Richard De Schutter retiring following the 2024 Annual Meeting. The Board has temporarily expanded to 11 members and will revert to 10 after the meeting. Karen brings expertise in human capital management and corporate governance, aiming to contribute to the company's growth strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
management
-
Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) reported strong fourth-quarter and full-year 2023 financial results, with revenue reaching $1.173 billion and $4.146 billion, respectively. Despite a GAAP net loss of $54 million for the quarter and $260 million for the year, adjusted EBITDA stood at $231 million for the quarter and $738 million for the year. Revenue growth was driven by all segments, with a 10% increase for the full year on a reported basis and 12% on a constant currency basis. The company also provided a positive financial outlook for 2024, with projected revenue of $4.600 - $4.700 billion and adjusted EBITDA of $840 - $890 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.78%
Tags
earnings
-
Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
earnings
Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) has announced the FDA approval of the TENEO Excimer Laser Platform for LASIK vision correction surgery. The platform offers accuracy, efficiency, and usability advantages, with unique features such as advanced eye tracking, high-speed laser, customizable touchscreen, and compact design. It is indicated for patients with myopic astigmatism up to -10.00 D MRSE, 22 years or older, and with stable refraction in the last 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.11%
Tags
fda approval
-
Rhea-AI Summary
Bausch + Lomb Corporation (BLCO) announced that Chairman and CEO Brent Saunders will participate in a fireside chat with investors at the 42nd Annual J.P. Morgan Healthcare Conference. Other company executives will also participate. A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch + Lomb website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
conferences
-
Rhea-AI Summary
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced the success of its ONE by ONE and Biotrue Eye Care Recycling programs, collecting 76,645,000 million units, or 464,100 pounds, of used contact lenses, eye care, and lens care materials in the United States. This initiative helps keep recyclable plastic and aluminum eye health packaging materials out of landfills and oceans, contributing to environmental sustainability and human health.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.66%
Tags
none
Rhea-AI Summary
Bausch + Lomb Corporation reported revenues of $1.007 billion in the third quarter of 2023, a 7% increase compared to the same period last year. The company's GAAP net loss was $84 million. Adjusted EBITDA was $187 million. Revenue growth was driven by the Vision Care and Surgical segments. The company raised its full-year revenue guidance to $4.035 - $4.085 billion and adjusted EBITDA guidance to $710 - $760 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
earnings
-
Rhea-AI Summary
Bausch + Lomb to present studies and data at the American Academy of Ophthalmology annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
Rhea-AI Summary
Bausch + Lomb Corporation to release Q3 2023 financial results on Nov. 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
earnings
Rhea-AI Summary
Bausch + Lomb to present at AAOpt annual meeting, highlighting the results of a study on Blink Triple Care Lubricating Dry Eye Drops and data on MIEBO prescription eye drops and INFUSE Multifocal contact lenses. Educational events will also be hosted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none
Bausch + Lomb Corp

NYSE:BLCO

BLCO Rankings

BLCO Stock Data

5.80B
40.07M
88.99%
11.28%
0.59%
Ophthalmic Goods Manufacturing
Manufacturing
Link
Canada
Vaughan

About BLCO

bausch and lomb corp is a renewables and environment company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.